1: Li S, Ma JA. Core-structure-inspired asymmetric addition reactions: enantioselective synthesis of dihydrobenzoxazinone- and dihydroquinazolinone-based anti-HIV agents. Chem Soc Rev. 2015 Nov 7;44(21):7439-48. doi: 10.1039/c5cs00342c. Review. PubMed PMID: 26177889.
2: Badawy SI, Lee TJ, Menning MM. Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 Nov 17;1(4):E33. PubMed PMID: 14727898; PubMed Central PMCID: PMC2750457.
3: Xie M, Ziemba TM, Maurin MB. Sublimation characterization and vapor pressure estimation of an HIV nonnucleoside reverse transcriptase inhibitor using thermogravimetric analysis. AAPS PharmSciTech. 2003;4(2):E23. PubMed PMID: 12916905; PubMed Central PMCID: PMC2750601.
4: Chen H, Chen W, Gan LS, Mutlib AE. Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos. 2003 Jan;31(1):122-32. PubMed PMID: 12485961.
5: Chen H, Shockcor J, Chen W, Espina R, Gan LS, Mutlib AE. Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. Chem Res Toxicol. 2002 Mar;15(3):388-99. PubMed PMID: 11896687.
6: Second-generation drugs fight resistant virus. STEP Perspect. 1999 Winter;99(1):3. PubMed PMID: 11367160.
7: Whitson S. Drug watch. Posit Aware. 1999 May-Jun;10(3):16-7. PubMed PMID: 11366758.
8: New nonnucleoside reverse transcriptase inhibitors. GMHC Treat Issues. 1999 Feb;13(2):10. PubMed PMID: 11366114.
9: Parsons RL Jr. Development of commercially viable enantioselective processes for HIV-1 NNRTIs. Curr Opin Drug Discov Devel. 2000 Nov;3(6):783-92. PubMed PMID: 19649906.
10: Kauffman GS, Harris GD, Dorow RL, Stone BR, Parsons RL Jr, Pesti JA, Magnus NA, Fortunak JM, Confalone PN, Nugent WA. An efficient chiral moderator prepared from inexpensive (+)-3-carene: synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963. Org Lett. 2000 Oct 5;2(20):3119-21. PubMed PMID: 11009360.
11: Aubry AF, Sebastian D, Hobson T, Xu JQ, Rabel S, Xie M, Gray V. In-use testing of extemporaneously prepared suspensions of second generation non-nucleoside reversed transcriptase inhibitors in support of phase I clinical studies. J Pharm Biomed Anal. 2000 Aug 15;23(2-3):535-42. PubMed PMID: 10933547.
12: Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, Diamond S, Jeffrey S, Klabe RM, Cordova BC, Garber S, Logue K, Trainor GL, Anderson PS, Erickson-Viitanen SK. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2000 May 18;43(10):2019-30. PubMed PMID: 10821714.
13: Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, Trainor GL, Anderson PS, Erickson-Viitanen SK. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7. PubMed PMID: 10582878; PubMed Central PMCID: PMC89583.